MIST

Milestone Pharmaceuticals Inc. (MIST) | Rumor.io

Milestone Pharmaceuticals

MIST

Attention (50-day avg)0%

Attention rank (50-day avg)#1,193

Bullish sentiment (50-day avg)68%

Price to earnings ratio-1.05

Market capitalization99M

Earnings per share-0.65

Dividend yield (TTM)—

Revenue (annual)1.5M

Net income (annual)-63.1M

Social

What share of all stock conversation is about MIST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 25

The company's drug, CARDAMYST, has been successful in treating patients with supraventricular tachycardia (SVT), with several real-world experiences showing positive results.
The company's commercial sales have been slow, but insiders are not stepping up to buy the stock, which has raised concerns about management's confidence in the company.
There is speculation about the company's potential for growth, with some analysts expecting a significant deal for European distribution and potential tie-ins to other opportunities, which could provide a boost to the company's cash position and future growth.

Generated by AI

Sentiment

Of the messages about MIST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	54.05% +12.59	59.85% -16.47	82.91% -0.47
Bearish	—	45.95% -12.59	40.15% +16.47	17.09% +0.47

Bullish· Aug 12

The company has expanded its commercial coverage, with formulary coverage increasing from 25% to over 50% by early August, following wins at UnitedHealthcare and other insurers.
The stock has seen a rebound after a 20% drop, with the author adding 30,000 shares at an average price of $1.03, expecting a big uptick in Q3.
The company's institutional ownership has risen to 33%, indicating that institutions are taking a long-term view on the company's potential success.

Bearish· May 13

$MIST's recent performance is disappointing, with the stock down 16% despite a good report.
The company's high expenses and expectations for future sales have made it a target for short sellers.
The cost-effectiveness of the PIP alternative to Cardamyst is a major concern for the company's commercial success.

Generated by AI

Topics

Of the messages about MIST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	31.82%	75.68%	58.23%
Technical Analysis	—	13.64%	5.41%	18.96%
Analysts	—	27.27%	10.81%	13.25%
Earnings	—	27.27%	8.11%	2.81%
Controversies	—	0%	0%	1.35%
Macro	—	0%	0%	5.4%

Analysts· May 4

Analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways with a price target of $120.00.
Trucchio has a -24.8% average return and 22.8% success rate, ranking him 0 stars out of 5.
Trucchio covers the Healthcare sector, focusing on stocks including Milestone Pharmaceuticals.

Announcements· Jul 11

Milestone Pharmaceuticals Inc. ($MIST) received a new PDUFA date of Dec 13, 2025, for CARDAMYST nasal spray for PSVT after FDA accepted its CRL resubmission.
The company extended its $75M royalty deal with RTW through year-end, previously requiring approval by Sept 30 to get the proceeds from the royalty agreement.
Milestone Pharmaceuticals priced a $52.5M public offering of common and pre-funded shares, Series A and Series B warrants to fund etripamil's clinical development and commercial launch for PSVT, and general corporate purposes.

Technical Analysis· Jul 24

$MIST has broken out and traded to $10.17, with support levels at $9.50 and $9.
The stock has formed a head and shoulder pattern, which is a reversal pattern that can indicate a breakdown, with a potential target of $8.
$MIST is nearing its 200-day moving average ($11.88) and has shown a cup and handle formation, indicating potential upside.

Generated by AI

Community

Of the messages about MIST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	80.57%	80.7%	52.94%
Newcomers	33.33%	19.43%	19.3%	47.06%

Regulars· Sep 25

The adoption of CARDAMYST, Milestone Pharmaceuticals' key product, is gaining traction, with patients becoming strong advocates after positive real-world experiences, and insiders may consider an acquisition at several times today's valuation.
Management's lack of confidence in the company's fundamentals and failure to communicate with shareholders is causing concern, and the absence of buying from insiders is a red flag.
The slow commercial sales of CARDAMYST are a major concern, and the company's fundamentals are being questioned, with some users suggesting that the stock's value is being manipulated by hedge funds.

Newcomers· Aug 12

Newcomers are adding to their positions in $MIST, citing a 20% drop on a 200K miss on a new drug as a buying opportunity, with one user adding 30,000 shares at an average of 1.03.
Institutional ownership of $MIST has risen to 33%, which some users believe is a sign that institutions are expecting the company to be successful, and are taking advantage of the stock's current price to acquire shares from retail holders.
One user is speculating that $MIST's slow growth is due to the company giving away scripts and coverage to expand its reach, and is expecting a big breakout in the coming months, with a potential price of $3.00.

Generated by AI

News

Milestone Pharmaceuticals at H.C. Wainwright: launch gains and afib push

14d agoInvesting.com

Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead

21d agoInvesting.com

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis

26d agofinance.yahoo.com

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

MONTREAL and CHARLOTTE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at, and participate in, the following upcoming investor conferences. Conference Details Wells Fargo 21st Annual Healthcare Conference Format:Fireside chat and 1x1sPresentation Date:September 8, 2026Time:1:30 pm ETLocation:Bos

28d agoYahoo Finance

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and WorkMONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) af

1mo agoYahoo Finance

Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

Milestone Pharmaceuticals Inc (NASDAQ:MIST) shares gained 3. 9% on Friday after the company announced that the first patient had been enrolled in its Phase 3 ReVeRA-301 study of etripamil for atrial fibrillation with rapid ventricular rate (AFib-RVR).

1mo agoYahoo Finance

Also Discussed

Investors talking about MIST also mention

#	Name	Attention
1	Grace Therapeutics, Inc.GRCE	0%new
2	Aldeyra Therapeutics, Inc.ALDX	0%+0
3	Nuvation Bio Inc.NUVB	0%0
4	Immuron Ltd. Sponsored ADRIMRN	0%0
5	Natuzzi S.p.A. ADRNTZ	0%0
6	SCPH - scPharmaceuticals Inc.	——
7	THTX - Theratechnologies Inc.	——
8	Outlook Therapeutics Inc.OTLK	0.01%-0.01
9	UroGen Pharma Ltd.URGN	0%new
10	Fortress Biotech, Inc.FBIO	0%0

Milestone Pharmaceuticals Inc.

Healthcare
Biotechnology

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate. The company centers its work on self-administered therapies that can be used outside the emergency department, addressing episodic heart rhythm conditions through a nasal spray delivery format. Based in Montreal, Canada, Milestone Pharmaceuticals Inc. serves the cardiovascular and biotechnology markets through its current product portfolio and ongoing clinical and commercial activities in the United States and Canada.

Website

Location

1111 Dr. Frederik-Philips Boulevard

Montreal, QC, H4M 2X6

Canada

Social

What share of all stock conversation is about MIST?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% +0	0% 0

Sep 25

The company's drug, CARDAMYST, has been successful in treating patients with supraventricular tachycardia (SVT), with several real-world experiences showing positive results.
The company's commercial sales have been slow, but insiders are not stepping up to buy the stock, which has raised concerns about management's confidence in the company.
There is speculation about the company's potential for growth, with some analysts expecting a significant deal for European distribution and potential tie-ins to other opportunities, which could provide a boost to the company's cash position and future growth.

Generated by AI

Sentiment

Of the messages about MIST that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	54.05% +12.59	59.85% -16.47	82.91% -0.47
Bearish	—	45.95% -12.59	40.15% +16.47	17.09% +0.47

Bullish· Aug 12

The company has expanded its commercial coverage, with formulary coverage increasing from 25% to over 50% by early August, following wins at UnitedHealthcare and other insurers.
The stock has seen a rebound after a 20% drop, with the author adding 30,000 shares at an average price of $1.03, expecting a big uptick in Q3.
The company's institutional ownership has risen to 33%, indicating that institutions are taking a long-term view on the company's potential success.

Bearish· May 13

$MIST's recent performance is disappointing, with the stock down 16% despite a good report.
The company's high expenses and expectations for future sales have made it a target for short sellers.
The cost-effectiveness of the PIP alternative to Cardamyst is a major concern for the company's commercial success.

Generated by AI

Topics

Of the messages about MIST that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	31.82%	75.68%	58.23%
Technical Analysis	—	13.64%	5.41%	18.96%
Analysts	—	27.27%	10.81%	13.25%
Earnings	—	27.27%	8.11%	2.81%
Controversies	—	0%	0%	1.35%
Macro	—	0%	0%	5.4%

Analysts· May 4

Analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways with a price target of $120.00.
Trucchio has a -24.8% average return and 22.8% success rate, ranking him 0 stars out of 5.
Trucchio covers the Healthcare sector, focusing on stocks including Milestone Pharmaceuticals.

Announcements· Jul 11

Milestone Pharmaceuticals Inc. ($MIST) received a new PDUFA date of Dec 13, 2025, for CARDAMYST nasal spray for PSVT after FDA accepted its CRL resubmission.
The company extended its $75M royalty deal with RTW through year-end, previously requiring approval by Sept 30 to get the proceeds from the royalty agreement.
Milestone Pharmaceuticals priced a $52.5M public offering of common and pre-funded shares, Series A and Series B warrants to fund etripamil's clinical development and commercial launch for PSVT, and general corporate purposes.

Technical Analysis· Jul 24

$MIST has broken out and traded to $10.17, with support levels at $9.50 and $9.
The stock has formed a head and shoulder pattern, which is a reversal pattern that can indicate a breakdown, with a potential target of $8.
$MIST is nearing its 200-day moving average ($11.88) and has shown a cup and handle formation, indicating potential upside.

Generated by AI

Community

Of the messages about MIST, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	80.57%	80.7%	52.94%
Newcomers	33.33%	19.43%	19.3%	47.06%

Regulars· Sep 25

The adoption of CARDAMYST, Milestone Pharmaceuticals' key product, is gaining traction, with patients becoming strong advocates after positive real-world experiences, and insiders may consider an acquisition at several times today's valuation.
Management's lack of confidence in the company's fundamentals and failure to communicate with shareholders is causing concern, and the absence of buying from insiders is a red flag.
The slow commercial sales of CARDAMYST are a major concern, and the company's fundamentals are being questioned, with some users suggesting that the stock's value is being manipulated by hedge funds.

Newcomers· Aug 12

Newcomers are adding to their positions in $MIST, citing a 20% drop on a 200K miss on a new drug as a buying opportunity, with one user adding 30,000 shares at an average of 1.03.
Institutional ownership of $MIST has risen to 33%, which some users believe is a sign that institutions are expecting the company to be successful, and are taking advantage of the stock's current price to acquire shares from retail holders.
One user is speculating that $MIST's slow growth is due to the company giving away scripts and coverage to expand its reach, and is expecting a big breakout in the coming months, with a potential price of $3.00.

Generated by AI

Milestone Pharmaceuticals

Social

Sep 25

Bullish· Aug 12

Bearish· May 13

Analysts· May 4

Announcements· Jul 11

Technical Analysis· Jul 24

Regulars· Sep 25

Newcomers· Aug 12

Milestone Pharmaceuticals at H.C. Wainwright: launch gains and afib push

Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

Also Discussed

Milestone Pharmaceuticals Inc.

Company Information

Location

Social

Sep 25

Bullish· Aug 12

Bearish· May 13

Analysts· May 4

Announcements· Jul 11

Technical Analysis· Jul 24

Regulars· Sep 25

Newcomers· Aug 12

Milestone Pharmaceuticals at H.C. Wainwright: launch gains and afib push

Milestone Pharmaceuticals at Wells Fargo: launch gains, bigger test ahead

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

Also Discussed